Superficial Punctate Keratitis Treatment Market Report 2026

The superficial punctate keratitis treatment market size has grown strongly in recent years. It will grow from $5.23 billion in 2025 to $5.58 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing prevalence of dry eye conditions, rising screen exposure related eye strain, growing awareness of corneal surface disorders, wider availability of ophthalmic pharmaceuticals, expansion of outpatient eye care services.

The superficial punctate keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing adoption of digital ophthalmology tools, rising demand for targeted ocular therapies, expansion of tele-ophthalmology services, growing focus on chronic eye condition management, increasing investment in precision eye care treatments. Major trends in the forecast period include increasing adoption of advanced lubricating eye formulations, rising use of anti-inflammatory and immunomodulatory therapies, growing integration of digital eye care platforms, expansion of minimally invasive spk treatments, enhanced focus on personalized ocular therapy.

The increasing prevalence of eye-related diseases is expected to fuel the growth of the superficial punctate keratitis treatment market in the coming years. Eye diseases encompass a broad range of conditions that affect vision and overall ocular health, including infections, degenerative disorders, and structural abnormalities. The rising incidence of these conditions is largely attributed to aging populations, prolonged screen exposure, higher rates of diabetes, and environmental influences such as pollution and ultraviolet radiation. Treatments for superficial punctate keratitis, including lubricating eye drops, antibiotics, and anti-inflammatory medications, are used to relieve pain, reduce inflammation, and support healing in eye diseases that damage the corneal surface. For example, in May 2024, according to the Office for Health Improvement and Disparities, a UK-based government body, England recorded more than 8.9 million vision outpatient attendances in the financial year ending 2023, corresponding to a rate of 15,362 per 100,000 population, an increase from 14,613 in the prior year. Consequently, the growing prevalence of eye diseases is driving demand for superficial punctate keratitis treatments.

Leading players in the superficial punctate keratitis treatment market are prioritizing the development of innovative solutions, particularly advanced eye drop formulations, to target underlying inflammation and deliver effective, non-invasive treatment options. Eye drops are liquid formulations intended for direct ocular administration and are widely used to manage symptoms such as irritation, dryness, inflammation, and infection. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, introduced CYCLOTEARS eye drops in India and other international markets for patients with inflammatory dry eye disease (DED). This product is the world’s first dry eye therapy to incorporate the company’s self-emulsifying drug delivery system (SEDDS) technology, marking a significant advancement in the treatment of ocular inflammation. The innovative formulation improves drug absorption and therapeutic efficacy, providing enhanced relief for patients.

In July 2024, Bausch + Lomb Corporation, a Canada-based eye health company, acquired Trukera Medical for an undisclosed consideration. Through this acquisition, Bausch + Lomb aims to expand its surgical footprint in the United States and reinforce its capabilities in dry eye management by integrating Trukera’s scoutPro device, which supports pre-surgical evaluation and optimization. Trukera Medical is a US-based company that specializes in diagnostic technologies, including the scoutPro device, for assessing corneal health and diagnosing dry eye disease.

Major companies operating in the superficial punctate keratitis treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc (GSK), Alcon Inc., Bausch + Lomb Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals plc, Santen Pharmaceutical Co. Ltd., Prestige Consumer Healthcare Inc., Dompé Farmaceutici S.p.A., OASIS Medical Inc., Bruschettini S.r.l., Allergan plc, CONTACARE Ophthalmics Pvt. Ltd., Prevego Healthcare Ltd.

North America was the largest region in the superficial punctate keratitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the superficial punctate keratitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the superficial punctate keratitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the superficial punctate keratitis treatment market by increasing costs of imported pharmaceutical ingredients, ophthalmic devices, diagnostic tools, and packaging materials used across pharmacological and minimally invasive treatment solutions. Hospitals and ophthalmology clinics in North America and Europe are most affected due to reliance on imported active pharmaceutical ingredients and medical consumables, while Asia-Pacific faces pricing pressure on export-oriented drug manufacturing. These tariffs are contributing to higher treatment costs and reimbursement challenges. However, they are also encouraging local drug formulation, domestic manufacturing of ophthalmic products, and regional supply chain strengthening for eye care solutions.

The superficial punctate keratitis treatment market research report is one of a series of new reports that provides superficial punctate keratitis treatment market statistics, including superficial punctate keratitis treatment industry global market size, regional shares, competitors with a superficial punctate keratitis treatment market share, detailed superficial punctate keratitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the superficial punctate keratitis treatment industry. This superficial punctate keratitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Superficial punctate keratitis (SPK) treatment involves managing corneal irritation caused by factors such as dry eye disease, infections, or environmental stressors. It includes the use of lubricating eye drops, anti-inflammatory medications, and treatment of underlying conditions to support healing. The goal of treatment is to ease discomfort, reduce inflammation, and restore corneal health.

The main product types in the superficial punctate keratitis treatment market include pharmacological treatments, surgical procedures, minimally invasive interventions, digital health solutions such as telemedicine and mobile applications, and other product categories. Pharmacological treatments consist of medications including antibiotics, antifungals, and anti-inflammatory eye drops used to control infections and reduce inflammation. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end users such as hospitals, ophthalmology clinics, home care settings, and ambulatory surgical centers.

The superficial punctate keratitis treatment market consists of revenues earned by entities through services such as diagnosis and consultation, prescription services, specialized therapeutic procedures, post-treatment monitoring and follow-up, patient education, and preventive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The superficial punctate keratitis treatment market also includes sales of lubricating eye drops and artificial tears, topical medications, contact lenses, diagnostic tools, UV protection glasses, and shields. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.